4/1/2008

A Phase III trial of imaging agent CorVue, produced by King Pharmaceuticals, found that CorVue can identify myocardial ischemia during cardiac pharmacologic stress SPECT imaging as well as adenosine does and may cause fewer side effects, a company press release said.

Full Story:
Google

Related Summaries